The Cancer Drug Development Forum – CDDF is the platform for all stakeholders involved in the development of cancer drugs.

Accelerating the Development and Delivery of

Effective Oncology Treatments

to Patients

 

Cancer Drug Development Forum (CDDF) is a neutral, non–competitive platform

for multi-stakeholder discussions and collaboration in the development of cancer drugs.

 

Unique Multi-Stakeholder Platform

Patients

Patients are the cornerstone of CDDF’s mission and central to our multi-stakeholder discussions. Patients and advocacy groups are invited to join the CDDF multi-stakeholder community and make their voices heard. Check out collaborative opportunities and grants available to patients.

Industry

The CDDF provides the healthcare industry with unique opportunities to collaborate with diverse stakeholders and take part in open dialogue to accelerate oncology drug development. Discover the CDDF Industry Membership Program and engage with key experts in oncology.

Academia

The CDDF fosters advancement and innovation in cancer research by creating a collaborative platform for academics to share knowledge and expertise with a multi-stakeholder audience. Join CDDF’s discussions on the latest developments and explore opportunities to contribute.

Regulators & HTAs

The CDDF convenes discussions on key topics in oncology, fostering a balanced exchange of perspectives. Regulators and HTA agencies can gain valuable insights and stay informed on emerging trends through our productive dialogue. Explore collaboration opportunities and join our community.

CANCER DRUG DEVELOPMENT FORUM

The leading non-competitive drug development platform working to stimulate the advancement and accessibility of cancer treatment.

Executive Summary: CDDF & AAADV Workshop – Challenges in the Landscape of a Global Development Strategy Including Patient Access (30-31 March 2026, BE)

The Cancer Drug Development Forum (CDDF) is delighted to announce that the executive summary of the CDDF & AAADV joint workshop on “Challenges in the Landscape of a Global Development Strategy Including Patient Access” has been published today. This...

[News from ACT EU] – Clinical Trials Information System (CTIS): training and support

Check out the publication of a new EMA document of frequently asked questions (FAQ) for sponsors on the Clinical Trials Information System (CTIS):...

Interim Report: ACT EU pilots on consolidated scientific and regulatory advice

The interim results from the ACT EU pilots on consolidated scientific and regulatory advice have been published and available to stakeholders. These pilots were launched to offer harmonised advice on how to improve the quality of applications for clinical trials and...

[CDDF NEW WHITE PAPER: Challenges and Potential Solutions to Advance Global Cancer Drug Development]

We are delighted to announce that CDDF’s new white paper, Challenges and Potential Solutions to Advance Global Cancer Drug Development, has been published in the journal Therapeutic Innovation & Regulatory Science. This paper reflects on multi-stakeholder...

CDDF Diversity Initiative: In-Person Meeting in Brussels Today

Following several work package meetings over the past 10 months, the final project meeting for the Diversity Initiative is in full swing in Brussels. Our multi-stakeholder working group members and experts have gathered to advance their work on developing and...

[EMA News] Public Consultation: Concept Paper on Guideline Revision on Good Pharmacogenomic Practice

🔔📢The European Medicines Agency has published for public consultation: a Concept paper on the guideline revision on good pharmacogenomic practice. Since its initial publication in 2018, the guideline on good pharmacogenomic practice has played a crucial role in...

Multi-stakeholder Interview: Get an Inside Look at the CDDF Annual Conference 2026

We are excited to share interview clips featuring a diverse group of stakeholders at this year’s CDDF annual conference. Held in Ghent on 9-11 February, the meeting highlighted multi-stakeholder collaboration as the cornerstone of our shared mission to improve cancer...

Executive Summary: CDDF Annual Conference 2026 – “Cancer Clinical Research in a Changing Global Environment” (9-11 Feb 2026)

The Cancer Drug Development Forum (CDDF) is delighted to announced that the executive summary of this year’s Annual Conference has been published today and is available to all our stakeholders. This multi-stakeholder conference took place on 9-11 February 2026 in...

ACT EU: MSP AG – Call for Expressions of Interest

📢 🔔Take a look at the below 'Call for Expressions of Interest' from the Multi-stakeholder Platform Advisory Group (MSP AG) under ACT EU: ▶️ Message from ACT EU: MSP AG "Call for Expression of Interest – Focus Group on the review of the Guideline for the notification...

[NEW PUBLICATION: WHITE PAPER – Innovative Oncology Trial Designs: Time to Act]

While the CDDF Annual Conference 2026 is in full swing, we are thrilled to announce the publication of our latest white paper: “Innovative oncology trial designs: Time to act – A review with recommendations of the Cancer Drug Development Forum.” This paper was largely...

CDDF Webinar: Bayesian Approaches in Drug Development (July 2024)

The recording of the recent CDDF webinar on Bayesian Approaches in Drug Development is available here. Enjoy the insightful talks from DRob Hemmings (Consilium, UK) followed by an interactive Q&A session.

CDDF & Oncology News

Check out the recent updates within the CDDF and the latest news in the community of cancer research

CDDF Brochure

Access the CDDF Brochure here

 

Join the CDDF community to find ways to accelerate oncology drug development and deliver optimal treatment to cancer patients

COLLABORATION IS THE KEY

TO IMPROVING OUTCOMES

FOR CANCER PATIENTS

Cancer Drug Development Forum asbl
Registered office: c/o BLSI, Clos Chapelle-aux-Champs 30, 1200 Woluwe Saint Lambert, Belgium
Register of legal entities: the French Speaking Enterprise Court in Brussels
Enterprise number: 738.523.752

Privacy Policy

info@cddf.org
Tel: +32 2 880 62 70